Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The Bells of Hope community provides support and inspiration, fostering unity ...

We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood cell called plasma cells.

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

A stem cell transplant can be a good treatment for multiple myeloma. A successful transplant gives someone with multiple myeloma new, healthy bone marrow. It replaces the bone marrow harmed by myeloma ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...